Stereotactic Body Radiotherapy (sbrt) in Lung Oligometastatic Patients: Role of Local Treatments

Overview

Journal Radiat Oncol

Publisher Biomed Central

Specialties Oncology
Radiology

Date 2014 Apr 4

PMID 24694067

Citations 35

Authors

Pierina Navarria

Anna Maria Ascolese

Stefano Tomatis

Luca Cozzi

Fiorenza De Rose

Pietro Mancosu

Filippo Alongi

Elena Clerici

Francesca Lobefalo

Angelo Tozzi

Giacomo Reggiori

Antonella Fogliata

Marta Scorsetti

Affiliations

Soon will be listed here.

Abstract

Background: Data in the literature suggest the existence of oligometastatic disease, a state in which metastases are limited in number and site. Different kinds of local therapies have been used for the treatment of limited metastases and in the recent years reports on the use of Stereotactic Ablative radiotherapy (SABR) are emerging and the early results on local control are promising.

Patients And Methods: From October 2010 to February 2012, 76 consecutive patients for 118 lung lesions were treated. SABR was performed in case of controlled primary tumor, long-term of progression disease, exclusion of surgery, and number of metastatic sites ≤ 5. Different kinds of primary tumors were treated, the most common were lung and colon-rectal cancer. The total dose prescribed varied according to tumor site and maximum diameter. Dose prescription was 48 Gy in 4 fractions for peripheral lesions, 60 Gy in 8 fractions for central lesions and 60 Gy in 3 fractions for peripheral lesions with diameter ≤ 2 cm.

Results: Dosimetric planning objectives were met for the cohort of patients with in particular V98% = 98.1 ± 3.4% for the CTV and mean lung dose of 3.7 ± 3.8 Gy. Radiological response was obtained in the vast majority of patients. The local control at 1, 2 and 3 years was 95%, 89% and 89% respectively. No major pulmonary toxicity, chest pain or rib fracture occurred. The median follow up was 20 months (range 6-45 months). Overall Survival (OS) at 1, 2 and 3 years was 84.1%, 73% and 73% respectively.

Conclusions: SABR is feasible with limited morbidity and promising results in terms of local control, survival and toxicity.

Citing Articles

Stereotactic body radiotherapy with volumetric intensity-modulated arc therapy and flattening filter-free beams: dosimetric considerations.

Brekner M, Imhoff D, Rodel C, Filmann N, Licher J, Ramm U Strahlenther Onkol. 2023; 200(4):346-357.

PMID: 38092967 PMC: 10965745. DOI: 10.1007/s00066-023-02181-8.

Can Surgical Resection of Metastatic Lesions Be Beneficial to Pancreatic Ductal Adenocarcinoma Patients with Isolated Lung Metastasis?.

Yun W, Kwon W, Han Y, Sohn H, Kim H, Lee M Cancers (Basel). 2022; 14(9).

PMID: 35565195 PMC: 9099489. DOI: 10.3390/cancers14092067.

Stereotactic radiotherapy for lung oligometastases.

Falcinelli L, Menichelli C, Casamassima F, Aristei C, Borghesi S, Ingrosso G Rep Pract Oncol Radiother. 2022; 27(1):23-31.

PMID: 35402023 PMC: 8989443. DOI: 10.5603/RPOR.a2022.0002.

Repeated Multimodality Ablative Therapies for Oligorecurrent Pulmonary Metastatic Disease.

Macagno A, de Nonneville A, Annede P, Piana G, Pougnet I, Daidj N Curr Oncol. 2022; 29(3):1683-1694.

PMID: 35323340 PMC: 8947282. DOI: 10.3390/curroncol29030140.

Modern evidence and future prospects of external body radiation therapy for lung oligometastases of breast cancer.

Wada Y, Hashimoto M Transl Cancer Res. 2022; 9(8):5077-5086.

PMID: 35117873 PMC: 8799217. DOI: 10.21037/tcr.2020.02.55.

References

Bonomo P, Livi L, Rampini A, Meattini I, Agresti B, Simontacchi G . Stereotactic body radiotherapy for cardiac and paracardiac metastases: University of Florence experience. Radiol Med. 2013; 118(6):1055-65. DOI: 10.1007/s11547-013-0932-0. View

Zhang Y, Xiao J, Zhang H, Yin W, Hu Y, Song Y . Stereotactic body radiation therapy favors long-term overall survival in patients with lung metastases: five-year experience of a single-institution. Chin Med J (Engl). 2012; 124(24):4132-7. View

Rusthoven K, Kavanagh B, Cardenes H, Stieber V, Burri S, Feigenberg S . Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009; 27(10):1572-8. DOI: 10.1200/JCO.2008.19.6329. View

Casamassima F, Livi L, Masciullo S, Menichelli C, Masi L, Meattini I . Stereotactic radiotherapy for adrenal gland metastases: university of Florence experience. Int J Radiat Oncol Biol Phys. 2011; 82(2):919-23. DOI: 10.1016/j.ijrobp.2010.11.060. View

Kopetz S, Chang G, Overman M, Eng C, Sargent D, Larson D . Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009; 27(22):3677-83. PMC: 2720081. DOI: 10.1200/JCO.2008.20.5278. View

Fong Y, Cohen A, Fortner J, Enker W, Turnbull A, Coit D . Liver resection for colorectal metastases. J Clin Oncol. 1997; 15(3):938-46. DOI: 10.1200/JCO.1997.15.3.938. View

Holy R, Piroth M, Pinkawa M, Eble M . Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther Onkol. 2011; 187(4):245-51. DOI: 10.1007/s00066-011-2192-z. View

Milano M, Katz A, Muhs A, Philip A, Buchholz D, Schell M . A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer. 2007; 112(3):650-8. DOI: 10.1002/cncr.23209. View

Zelefsky M, Greco C, Motzer R, Magsanoc J, Pei X, Lovelock M . Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2011; 82(5):1744-8. PMC: 4034682. DOI: 10.1016/j.ijrobp.2011.02.040. View

10.

Wang J, Huang Z, Lo S, Yuh W, Mayr N . A generalized linear-quadratic model for radiosurgery, stereotactic body radiation therapy, and high-dose rate brachytherapy. Sci Transl Med. 2010; 2(39):39ra48. DOI: 10.1126/scitranslmed.3000864. View

11.

Scorsetti M, Mancosu P, Navarria P, Tozzi A, Castiglioni S, Clerici E . Stereotactic body radiation therapy (SBRT) for adrenal metastases : a feasibility study of advanced techniques with modulated photons and protons. Strahlenther Onkol. 2011; 187(4):238-44. DOI: 10.1007/s00066-011-2207-9. View

12.

Lo S, Fakiris A, Teh B, Cardenes H, Henderson M, Forquer J . Stereotactic body radiation therapy for oligometastases. Expert Rev Anticancer Ther. 2009; 9(5):621-35. DOI: 10.1586/era.09.15. View

13.

Le Q, Loo B, Ho A, Cotrutz C, Koong A, Wakelee H . Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J Thorac Oncol. 2007; 1(8):802-9. View

14.

Park C, Papiez L, Zhang S, Story M, Timmerman R . Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys. 2008; 70(3):847-52. DOI: 10.1016/j.ijrobp.2007.10.059. View

15.

Alongi F, Arcangeli S, Filippi A, Ricardi U, Scorsetti M . Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist. 2012; 17(8):1100-7. PMC: 3425528. DOI: 10.1634/theoncologist.2012-0092. View

16.

Pastorino U, Buyse M, Friedel G, Ginsberg R, Girard P, Goldstraw P . Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997; 113(1):37-49. DOI: 10.1016/s0022-5223(97)70397-0. View

17.

Ricardi U, Filippi A, Guarneri A, Ragona R, Mantovani C, Giglioli F . Stereotactic body radiation therapy for lung metastases. Lung Cancer. 2011; 75(1):77-81. DOI: 10.1016/j.lungcan.2011.04.021. View

18.

Okunieff P, Petersen A, Philip A, Milano M, Katz A, Boros L . Stereotactic Body Radiation Therapy (SBRT) for lung metastases. Acta Oncol. 2006; 45(7):808-17. DOI: 10.1080/02841860600908954. View

19.

Hasselle M, Haraf D, Rusthoven K, Golden D, Salgia R, Villaflor V . Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2011; 7(2):376-81. DOI: 10.1097/JTO.0b013e31824166a5. View

20.

Milano M, Katz A, Schell M, Philip A, Okunieff P . Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2008; 72(5):1516-22. DOI: 10.1016/j.ijrobp.2008.03.044. View